PFE Pfizer, Inc. Common Stock
NYSE · Pharmaceuticals · Lihat di SEC EDGAR ↗ tutup Okt 6, 2026 10-K/10-Q Agu 4, 2026PFE Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
PFE Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
| Tanggal ex-dividen | Pemecahan | Tipe |
|---|---|---|
| 17 Nov. 2020 | 527-for-500 | Maju |
| 1 Juli 1999 | 3-for-1 | Maju |
| 1 Juli 1997 | 2-for-1 | Maju |
| 3 Juli 1995 | 2-for-1 | Maju |
| 1 April 1991 | 2-for-1 | Maju |
| 1 Juli 1983 | 2-for-1 | Maju |
Tentang Pfizer, Inc. Common Stock Tinjauan perusahaan dari Wikipedia
Pfizer Inc. () adalah sebuah perusahaan farmasi asal Amerika. Perusahaan ini merupakan salah satu perusahaan farmasi terbesar di dunia dan menempati peringkat ke-57 dalam daftar Fortune 500 tahun 2018.
Berkantor pusat di New York City, Pfizer mengembangkan dan memproduksi obat dan vaksin untuk berbagai macam disiplin medis, termasuk imunologi, onkologi, kardiologi, endokrinologi, dan neurologi. Produknya meliputi obat blockbuster Lipitor (atorvastatin), yang digunakan untuk menurunkan kolesterol darah LDL; Lyrica (pregabalin) untuk nyeri neuropatik dan fibromialgia; Diflucan (flukonazol), sebuah medikasi antijamur oral; Zithromax (azitromisin), sebuah antibiotik; Viagra (sildenafil) untuk disfungsi erektil; dan Celebrex (juga Celebra, selekoksib), sebuah obat antiinflamasi nonsteroid.
Pada tahun 2016, Pfizer Inc. diperkirakan akan bergabung dengan Allergan untuk membentuk "Pfizer plc", dalam sebuah kesepakatan yang diperkirakan bernilai US$160 miliar. Namun penggabungan tersebut dibatalkan pada bulan April 2016, karena adanya aturan baru dari Departemen Keuangan Amerika Serikat mengenai inversi pajak, sebuah metode penghindaran pajak yang dilakukan dengan cara bergabung dengan perusahaan dari luar Amerika Serikat.
Pada tanggal 19 Desember 2018, Pfizer mengumumkan penggabungan divisi perawatan kesehatan ritel miliknya dengan GlaxoSmithKline, di mana GlaxoSmithKline akan memegang 68% saham perusahaan tersebut.
Pfizer merupakan salah satu komponen dari Dow Jones Industrial Average mulai tahun 2004 hingga 2020, setelah perusahaan ini digantikan oleh Amgen. Penggantian tersebut mulai berlaku pada tanggal 31 Agustus 2020.
Sejarah
1849–2000
Pada tahun 1849, Pfizer didirikan di New York City oleh seorang Jerman-Amerika, Charles Pfizer (sebenarnya bernama Karl Pfizer) bersama sepupunya, Charles F. Erhart dari Ludwigsburg, Jerman. Perusahaan inipun diberi nama Charles Pfizer and Company, dengan fasilitas produksi di Bartlett Street, Williamsburg, Brooklyn. Perusahaan ini awalnya memproduksi sebuah antiparasit bernama santonin. Produk tersebut pun sangat laku, walaupun kemudian produk asam sitrat lah yang membuat Pfizer dapat tumbuh pesat pada dekade 1880-an. Perusahaan ini pun terus membeli properti untuk mengembangkan laboratorium dan pabriknya. Kantor pusat Pfizer awalnya berlokasi di Maiden Lane no. 81, Manhattan. Pada tahun 1906, penjualan tahunan Pfizer telah mencapai $3 juta.
Perang Dunia I menyebabkan kurangnya pasokan kalsium sitrat, yang biasanya Pfizer impor dari Italia untuk memproduksi asam sitrat, sehingga perusahaan ini pun mulai mencari pasokan alternatif. Ahli kimia Pfizer kemudian mengetahui bahwa sebuah jamur dapat memfermentasi gula menjadi asam sitrat, sehingga Pfizer mulai mengkomersialkan produksi asam sitrat dengan metode tersebut pada tahun 1919. Sebagai hasilnya, perusahaan inipun mengembangkan keahlian di bidang teknologi fermentasi. Keahlian tersebut lalu diaplikasikan untuk memproduksi antibiotik penisilin secara masal selama Perang Dunia II, karena adanya kebutuhan untuk merawat tentara Sekutu yang terluka. Sebagian besar penisilin yang dibawa oleh pasukan di D-Day diproduksi oleh Pfizer.
Penisilin menjadi sangat murah pada dekade 1940-an, sehingga Pfizer mulai mencari antibiotik lain yang dapat menghasilkan lebih banyak laba. Pfizer lalu menemukan Terramisin (oksitetrasiklin) pada tahun 1950, dan penemuan tersebut pun mengubah perusahaan ini dari sebuah produsen bahan kimia murni menjadi sebuah perusahaan farmasi berbasis riset. Pfizer mengembangkan sebuah program penemuan obat yang fokus pada sintesis vitro untuk mengembangkan risetnya di bidang teknologi fermentasi. Perusahaan ini juga mendirikan divisi kesehatan hewan pada tahun 1959, lengkap dengan sebuah peternakan dan fasilitas riset seluas 700-ekar (2,8 km2) di Terre Haute, Indiana.
Pada dekade 1950-an, Pfizer telah mendirikan kantor di Belgia, Brazil, Kanada, Kuba, Meksiko, Panama, Puerto Riko, dan Britania Raya. Pada tahun 1960, perusahaan ini memindahkan laboratorium risetnya dari New York City ke Groton, Connecticut. Pada tahun 1980, Pfizer meluncurkan Feldene (piroksikam), sebuah obat resep anti-inflamasi, yang kemudian menjadi produk pertama Pfizer yang penjualannya dapat mencapai satu miliar dolar. Selama dekade 1980-an dan 1990-an, pertumbuhan Pfizer didukung oleh penemuan dan pemasaran Zoloft, Lipitor, Norvasc, Zithromax, Aricept, Diflucan, dan Viagra.
2000–2010
Pada dekade ini, Pfizer tumbuh melalui penggabungan, termasuk dengan Warner–Lambert (2000), Pharmacia (2003), dan Wyeth (2009).
Pada tahun 2003, perusahaan ini mengakuisisi Esperion Therapeutics dengan harga $1,3 miliar (kemudian dijual pada tahun 2008), melindungi Lipitor dari ETC-216. Pada tahun 2004, Pfizer mengumumkan bahwa mereka akan mengakuisisi Meridica dengan harga $125 juta. Pada tahun 2005, perusahaan ini mengakuisisi Vicuron Pharmaceuticals dengan harga $1,9 miliar, Idun dengan harga hampir $300 juta, dan Angiosyn dengan harga $527 juta.
Pengembangan torsetrapib, sebuah obat untuk meningkatkan produksi HDL, atau "kolesterol baik", guna mengurangi LDL yang diduga menyebabkan penyakit hati, ditunda pada bulan Desember 2006. Selama uji klinis fase III yang melibatkan 15.000 pasien, lebih banyak kematian terjadi pada kelompok yang mengkonsumsi obat lebih banyak dari yang diharapkan, dan 60% peningkatan kematian pada pasien yang mengkonsumsi kombinasi torsetrapib dan Lipitor, daripada jika mengkonsumsi Lipitor saja. Pfizer merugi hampir $1 miliar dalam pengembangan obat gagal tersebut dan nilai pasar Pfizer pun ikut turun. Pada tahun yang sama, perusahaan ini juga mengumumkan bahwa mereka akan mengakuisisi PowerMed dan Rivax.
Pada bulan September 2009, Pfizer divonis bersalah atas pemasaran obat artritis Bextra secara ilegal, karena belum disetujui oleh Food and Drug Administration. Pfizer kemudian setuju untuk membayar uang damai sebesar $2,3 miliar.
BusinessWeek pada bulan Juli 2010 memberitakan bahwa Pfizer berupaya melawan produsen obat resep imitasi melalui tuntutan sipil, bukannya tuntutan kriminal. Pfizer pun mempekerjakan ahli narkotika dan ahli pabean dari seluruh dunia untuk melacak dan merangkai bukti-bukti yang dapat digunakan untuk menuntut produsen tersebut atas pelanggaran merek dagang. Sejak tahun 2007, Pfizer telah menghabiskan $3,3 juta untuk melakukan investigasi dan berhasil mendapat sekitar $5.1 juta, dengan potensi $5 juta lainnya masih dalam proses persidangan.
Pada tanggal 6 Mei 2013, Pfizer memberitahu Associated Press bahwa mereka akan mulai menjual Viagra langsung ke pasien melalui situs webnya.
2000: Akuisisi Warner–Lambert
Pfizer mengakuisisi Warner–Lambert pada tahun 2000 dengan harga $111,8 miliar, sehingga pada saat itu, menghasilkan perusahaan farmasi terbesar kedua di dunia. Warner–Lambert didirikan sebagai sebuah apotek di Philadelphia pada tahun 1856 oleh William R. Warner. Proses pelapisan tablet yang diciptakan oleh Warner membuatnya dapat masuk ke dalam Smithsonian Institution. Sementara Parke–Davis didirikan di Detroit pada tahun 1866 oleh Hervey Parke dan George Davis. Warner–Lambert mengambil alih Parke–Davis pada tahun 1976, dan mengakuisisi Wilkinson Sword pada tahun 1993, serta Agouron Pharmaceuticals pada tahun 1999.
2003: Akuisisi Pharmacia
Pada tahun 2003, Pfizer bergabung dengan Pharmacia. Penggabungan tersebut salah satunya didorong oleh keinginan untuk mendapatkan hak penuh atas Celebrex (selekoksib), sebuah inhibitor selektif COX-2 yang sebelumnya dipasarkan secara bersama-sama oleh Searle (diakuisisi oleh Pharmacia) dan Pfizer. Pada tahun-tahun berikutnya, Pfizer mengadakan restrukturisasi besar-besaran, termasuk menutup fasilitas dan mengurangi jumlah pekerjanya di Terre Haute, Indiana; Holland, Michigan; Groton, Connecticut; Brooklyn, New York; Sandwich, Amerika Serikat; dan Puerto Riko.
Pharmacia dibentuk melalui serangkaian penggabungan dan akuisisi. Para pendahulunya antara lain Searle, Upjohn, dan SUGEN.
Pada bulan April 1888, Searle didirikan di Omaha, Nebraska oleh Gideon Daniel Searle. Pada tahun 1908, Searle resmi didaftarkan sebagai sebuah badan hukum di Chicago, Illinois. Pada tahun 1941, Searle mendirikan kantor pusatnya di Skokie, Illinois. Searle kemudian diakuisisi oleh Monsanto Company pada tahun 1985.
The Upjohn Company adalah sebuah perusahaan farmasi yang didirikan pada tahun 1886 di Kalamazoo, Michigan, oleh Dr. William E. Upjohn. Perusahaan ini awalnya didirikan untuk memproduksi pil gembur, yang dirancang untuk dapat dicerna dengan mudah. Greenstone didirikan pada tahun 1993 oleh Upjohn sebagai divisi obat generik. Pada tahun 1995, Upjohn bergabung dengan Pharmacia, untuk membentuk Pharmacia & Upjohn. Pharmacia dibentuk pada bulan April 2000 melalui penggabungan Pharmacia & Upjohn dengan Monsanto Company dan G.D. Searle. Perusahaan hasil penggabungan tersebut pun berkantor pusat di Peapack, New Jersey. Divisi pertanian kemudian dipisah dari Pharmacia dengan nama Monsanto, sebagai bagian dari persiapan sebelum Pharmacia resmi diakuisisi oleh Pfizer.
Perubahan
GSK dan Pfizer menggabungkan bisnis produk perawatan kesehatan konsumen pada tahun 2019. GSK dan Pfizer memisahkan bisnis produk perawatan kesehatan konsumen membentuk Haleon pada tanggal 18 Juli 2022. Haleon saat ini produk perawatan kesehatan konsumen.
GSK dan Pfizer saat ini produk vaksin dan obat resep dokter.
Referensi
Pranala luar
Situs web resmi
Data bisnis Pfizer:
Sumber: Wikipedia, CC BY-SA 4.0 · Lihat di Wikipedia ↗
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | PFE | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E (TTM) | 36.2rata-rata 5T ≈27.9 | ≈27.9 | 31.0 | Nilai wajar |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | PFE | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| EBITDA Margin (Margin EBITDA) | 10.5%rata-rata 5T ≈8.7% | ≈8.7% | 8.3% | Tingkat teratas | |
| Margin Sebelum Pajak (TTM) | 6.6%rata-rata 5T ≈18.2% | ≈18.2% | 15.0% | Lemah | |
| Margin Laba Bersih (TTM) | 6.8%rata-rata 5T ≈17.4% | ≈17.4% | 10.4% | Lemah | |
| ROA (TTM) | 2.1%rata-rata 5T ≈7.6% | ≈7.6% | 9.8% | Lemah | |
| ROE (TTM) | 5.0%rata-rata 5T ≈17.6% | ≈17.6% | 25.3% | Lemah |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | PFE | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Utang / Ekuitas (MRQ) | 0.7rata-rata 5T ≈0.6 | ≈0.6 | 0.9 | Utang rendah | |
| Rasio Lancar (MRQ) | 1.3rata-rata 5T ≈1.2 | ≈1.2 | 1.6 | Likuiditas rendah | |
| Quick Ratio (Rasio Cepat) | 0.4rata-rata 5T ≈0.3 | ≈0.3 | 0.8 | Likuiditas rendah | |
| Utang Jangka Panjang / Ekuitas (MRQ) | 0.7rata-rata 5T ≈0.6 | ≈0.6 | 0.9 | Utang rendah |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | PFE | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | -1.7%rata-rata 5T ≈16.7% | ≈16.7% | · | · | |
| Revenue CAGR 3Y (CAGR Pendapatan 3T) | -14.8%rata-rata 5T ≈-3.3% | ≈-3.3% | · | · | |
| Revenue CAGR 5Y (CAGR Pendapatan 5T) | 8.5% | · | · | · | |
| EPS YoY | -3.5%rata-rata 5T ≈72.5% | ≈72.5% | · | · | |
| Net Income YoY (Laba Bersih YoY) | -3.2%rata-rata 5T ≈73.0% | ≈73.0% | · | · | |
| EPS CAGR 3Y (CAGR EPS 3T) | -37.1%rata-rata 5T ≈-34.9% | ≈-34.9% | · | · | |
| EPS CAGR 5Y (CAGR EPS 5T) | -3.6% | · | · | · | |
| Net Income CAGR 3Y (CAGR Laba Bersih 3T) | -37.2%rata-rata 5T ≈-34.8% | ≈-34.8% | · | · | |
| Net Income CAGR 5Y (CAGR Laba Bersih 5T) | -3.2% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | PFE | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 0.3rata-rata 5T ≈0.4 | ≈0.4 | 0.5 | Lemah | |
| Inventory Turnover (Perputaran Persediaan) | 1.5rata-rata 5T ≈2.6 | ≈2.6 | 1.5 | Sejajar | |
| Receivables Turnover (Perputaran Piutang) | 5.4rata-rata 5T ≈6.7 | ≈6.7 | 5.6 | Lemah | |
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$834.4K | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Dividen Yield, rasio pembayaran, riwayat dividen, CAGR 5 tahun
| Tanggal ex-dividen | Jumlah | Mata Uang | Imbal Hasil |
|---|---|---|---|
| Jul 24, 2026 | $0,43 | USD | ≈7.0% |
| Mei 8, 2026 | $0,43 | USD | ≈6.7% |
| Jan 23, 2026 | $0,43 | USD | ≈6.7% |
| Nov 7, 2025 | $0,43 | USD | ≈7.0% |
| Jul 25, 2025 | $0,43 | USD | ≈6.9% |
| Mei 9, 2025 | $0,43 | USD | ≈7.6% |
| Jan 24, 2025 | $0,43 | USD | ≈6.5% |
| Nov 8, 2024 | $0,42 | USD | ≈6.3% |
| Jul 26, 2024 | $0,42 | USD | ≈5.4% |
| Mei 9, 2024 | $0,42 | USD | ≈5.9% |
| Jan 25, 2024 | $0,42 | USD | ≈6.0% |
| Nov 9, 2023 | $0,41 | USD | ≈5.5% |
| Jul 27, 2023 | $0,41 | USD | ≈4.5% |
| Mei 11, 2023 | $0,41 | USD | ≈4.3% |
| Jan 26, 2023 | $0,41 | USD | ≈3.6% |
| Nov 3, 2022 | $0,40 | USD | ≈3.4% |
| Jul 28, 2022 | $0,40 | USD | ≈3.1% |
| Mei 12, 2022 | $0,40 | USD | ≈3.1% |
| Jan 27, 2022 | $0,40 | USD | ≈2.9% |
| Nov 4, 2021 | $0,39 | USD | ≈3.6% |
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Agu 3, 2026 | $0.77 | $0.69 | 11.4% |
| 31 Maret 2026 | $0.75 | $0.72 | 3.5% | |
| 31 Des. 2025 | $0.66 | $0.58 | 14.3% | |
| 30 Sep. 2025 | $0.87 | $0.64 | 36.0% | |
| 30 Juni 2025 | $0.78 | $0.59 | 32.9% | |
| 31 Maret 2025 | $0.92 | $0.67 | 37.5% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $62.58B | $63.63B | $59.55B | $101.17B | $81.29B | $41.65B | $40.91B | $40.83B | · | $52.82B | $48.85B | |
| Cost of Revenue | $16.07B | $17.85B | $24.95B | $34.34B | $30.82B | $8.48B | $8.05B | $8.99B | · | $12.32B | $9.65B | |
| SG&A Expense | $13.79B | $14.73B | $14.77B | $13.68B | $12.70B | $11.60B | $12.73B | $12.61B | · | $14.84B | $14.81B | |
| Interest Expense | $2.67B | $3.09B | $2.21B | $1.24B | $1.29B | $1.45B | $1.57B | $1.32B | · | $1.19B | $1.20B | |
| Interest Income | $603M | $545M | $1.62B | $251M | $36M | $73M | $225M | $333M | · | $470M | $471M | |
| Other Non-op | $-6.72B | $-4.39B | $-222M | $-1.06B | $4.88B | $-1.21B | $-3.50B | $-2.08B | · | $-3.79B | $-2.86B | |
| Pretax Income | $7.52B | $8.02B | $1.06B | $34.73B | $24.31B | $7.04B | $11.32B | $3.59B | · | $8.35B | $8.96B | |
| Income Tax | $-266M | $-28M | $-1.11B | $3.33B | $1.85B | $370M | $583M | $-266M | · | $1.12B | $1.99B | |
| Net Income | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.16B | $16.03B | $11.15B | · | $7.21B | $6.96B | |
| EPS (Basic) | $1.37 | $1.42 | $0.38 | $5.59 | $3.92 | $1.65 | $2.88 | $1.90 | · | $1.18 | $1.13 | |
| EPS (Diluted) | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 | $1.63 | $2.82 | $1.87 | · | $1.17 | $1.11 | |
| Shares (Basic) | 5,683,000,000 | 5,664,000,000 | 5,643,000,000 | 5,608,000,000 | 5,601,000,000 | 5,555,000,000 | 5,569,000,000 | 5,872,000,000 | · | 6,089,000,000 | 6,176,000,000 | |
| Shares (Diluted) | 5,713,000,000 | 5,700,000,000 | 5,709,000,000 | 5,733,000,000 | 5,708,000,000 | 5,632,000,000 | 5,675,000,000 | 5,977,000,000 | · | 6,159,000,000 | 6,257,000,000 | |
| EBITDA | $6.59B | $7.01B | $6.29B | $5.06B | $5.19B | · | $6.01B | $6.38B | · | $5.76B | $5.16B |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.14B | $1.04B | $2.85B | $416M | $1.94B | $1.79B | $1.12B | $1.14B | · | $2.60B | $3.64B | |
| Short-term Investments | · | · | · | · | · | $10.44B | $8.53B | $17.69B | · | $15.26B | $19.65B | |
| Receivables | $11.87B | $11.46B | $11.57B | $10.95B | $11.48B | $7.91B | $6.77B | $8.03B | $8.23B | $8.22B | $8.18B | |
| Inventory | $10.65B | $10.85B | $10.19B | $8.98B | $9.06B | $8.02B | $7.07B | $7.51B | $7.57B | $6.78B | $7.51B | |
| Other Current Assets | $2.81B | $4.25B | $4.91B | $5.02B | $3.82B | $3.65B | $2.36B | $2.46B | · | $2.25B | $2.15B | |
| Current Assets | $42.90B | $50.36B | $43.33B | $51.26B | $59.69B | $35.07B | $32.80B | $49.93B | · | $38.95B | $43.80B | |
| PP&E (Net) | $19.32B | $18.39B | $18.94B | $16.27B | $14.88B | $13.74B | $12.97B | $13.38B | · | $13.32B | $13.77B | |
| PP&E (Gross) | $36.70B | $34.88B | $34.98B | $31.45B | $29.95B | $28.41B | $27.96B | $29.98B | · | $28.12B | $27.27B | |
| Accum. Depreciation | $17.39B | $16.48B | $16.05B | $15.17B | $15.07B | $14.66B | $14.99B | $16.59B | · | $14.81B | $13.50B | |
| Goodwill | $71.26B | $68.53B | $67.78B | $51.38B | $49.21B | $49.56B | $48.18B | $42.93B | · | $54.45B | $48.24B | |
| Intangibles | $53.73B | $55.41B | $64.90B | $43.37B | $25.15B | $28.34B | $33.94B | $35.21B | · | $52.65B | $40.36B | |
| Other Non-current Assets | $9.63B | $9.82B | $12.47B | $13.16B | $7.68B | $4.88B | $4.20B | $2.80B | $3.02B | $3.32B | $3.42B | |
| Total Assets | $208.16B | $213.40B | $226.50B | $197.21B | $181.48B | $154.23B | $167.59B | $159.42B | · | $171.62B | $167.38B | |
| Accounts Payable | $5.24B | $5.63B | $6.71B | $6.81B | $5.58B | $4.28B | $3.89B | $4.67B | · | $4.54B | $3.62B | |
| Short-term Debt | $0 | $2.45B | $7.96B | $0 | $0 | $556M | $13.91B | $3.10B | · | $5.80B | · | |
| Current Liabilities | $36.98B | $42.99B | $47.79B | $42.14B | $42.67B | $25.92B | $37.30B | $31.86B | · | $31.11B | $29.40B | |
| Capital Leases | $2.29B | $2.29B | $2.63B | $2.60B | $2.51B | $1.11B | $1.03B | · | · | · | · | |
| Deferred Tax | $2.40B | $2.12B | $640M | $1.02B | $349M | $4.06B | $5.65B | $3.70B | $3.99B | $30.75B | $26.88B | |
| Other Non-current Liabilities | $14.72B | $14.15B | $16.54B | $13.18B | $9.74B | $6.67B | $6.89B | $5.85B | $5.69B | $6.34B | $5.26B | |
| Total Liabilities | $121.39B | $124.90B | $137.21B | $101.29B | $104.01B | $90.76B | $104.15B | $95.66B | · | $111.78B | $102.38B | |
| Long-term Debt | $64.64B | $61.15B | $63.79B | $35.44B | $37.83B | $4.00B | $37.42B | $37.69B | · | $31.40B | $28.82B | |
| Total Debt | $64.64B | $63.60B | $71.76B | $35.44B | $37.83B | $39.69B | $51.33B | $40.78B | · | $35.62B | $32.54B | |
| Common Stock | $481M | $480M | $478M | $476M | $473M | $470M | $468M | $467M | · | $461M | $459M | |
| Paid-in Capital | $94.47B | $93.60B | $92.63B | $91.80B | $90.59B | $88.67B | $87.43B | $86.25B | · | $82.69B | $81.02B | |
| Retained Earnings | $114.61B | $116.72B | $118.35B | $125.66B | $103.39B | $90.39B | $97.67B | $89.55B | $86.47B | $71.77B | $71.99B | |
| Treasury Stock | $115.02B | $114.76B | $114.49B | $113.97B | $111.36B | $110.99B | $110.80B | $101.61B | · | $84.36B | $79.25B | |
| AOCI | $-8.07B | $-7.84B | $-7.96B | $-8.30B | $-5.90B | $-5.31B | $-11.64B | $-11.28B | $-10.23B | $-11.04B | $-9.52B | |
| Stockholders' Equity | $86.48B | $88.20B | $89.01B | $95.66B | $77.20B | $63.24B | $63.14B | $63.41B | · | $59.54B | $64.72B | |
| Liabilities + Equity | $208.16B | $213.40B | $226.50B | $197.21B | $181.48B | $154.23B | $167.59B | $159.42B | · | $171.62B | $167.38B |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $6.59B | $7.01B | $6.29B | $5.06B | $5.19B | $4.68B | $5.75B | $6.38B | · | $5.76B | $5.16B | |
| Stock-based Comp | $799M | $877M | $525M | $872M | $1.18B | $755M | $687M | $923M | · | $691M | $669M | |
| Deferred Tax | $-2.13B | $-2.10B | $-3.44B | $-3.76B | $-4.29B | $-1.57B | $561M | $-2.20B | · | $-700M | $-20M | |
| Amort. of Intangibles | · | $5.30B | $4.70B | $3.60B | $3.70B | $3.40B | $4.50B | · | · | · | $3.80B | |
| Restructuring | $1.09B | $1.99B | $1.97B | $882M | $741M | $535M | $227M | $796M | · | $1.05B | $811M | |
| Other Non-cash | $-1.32B | $-1.07B | $3.21B | $-4.28B | $8.52B | · | $-11.03B | $-454M | · | $2.94B | $1.75B | |
| Operating Cash Flow | $11.70B | $12.74B | $8.70B | $29.27B | $32.58B | $14.40B | $12.59B | $15.83B | · | $16.19B | $14.69B | |
| CapEx | $2.63B | $2.91B | $3.91B | $3.24B | $2.71B | $2.23B | $2.05B | $1.98B | · | $1.82B | $1.40B | |
| Investing Cash Flow | $-1.35B | $2.65B | $-32.28B | $-15.78B | $-22.55B | $-4.27B | $-3.94B | $4.53B | · | $-7.79B | $-2.98B | |
| Debt Issued | $9.68B | $0 | $30.83B | $0 | $997M | $5.22B | $4.94B | $4.97B | · | $10.98B | $0 | |
| Net Debt Issued | $2.92B | $-2.25B | $28.26B | $-3.30B | $-1.01B | $1.22B | $-1.86B | $1.41B | · | $3.29B | $-3.00B | |
| Stock Repurchased | · | $0 | $0 | $2.00B | $0 | $0 | $8.87B | $12.20B | · | $5.00B | $6.16B | |
| Net Stock Activity | · | $0 | $0 | $-2.00B | $0 | $0 | $-8.87B | $-12.20B | · | $-5.00B | $-6.16B | |
| Financing Cash Flow | $-10.30B | $-17.14B | $26.07B | $-14.83B | $-9.82B | $-9.65B | $-8.48B | $-20.44B | · | $-9.23B | $-10.41B | |
| Net Change in Cash | $91M | $-1.81B | $2.45B | $-1.51B | $159M | $475M | $125M | $-205M | · | $-1.04B | $298M | |
| Taxes Paid | $4.69B | $3.60B | $3.15B | $7.87B | $7.43B | $3.15B | $3.66B | $3.65B | · | $2.52B | $2.38B | |
| Free Cash Flow | $9.07B | $9.84B | $4.79B | $26.03B | $29.87B | $12.15B | $10.41B | $13.79B | · | $14.08B | $13.12B | |
| Levered FCF | $6.31B | $6.73B | $256M | $24.91B | $28.68B | $10.79B | $8.96B | $12.55B | · | $13.05B | $12.18B |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 12.4% | 12.6% | 3.6% | 31.3% | 27.0% | 22.9% | 31.4% | 20.8% | · | 13.7% | 14.2% | |
| Pretax Margin | 12.0% | 12.6% | 1.8% | 34.6% | 29.9% | 17.9% | 34.2% | 22.1% | · | 15.8% | 18.4% | |
| EBITDA Margin | 10.5% | 11.0% | 10.8% | 5.1% | 6.4% | · | 11.6% | 11.9% | · | 10.9% | 10.6% | |
| ROA | 3.7% | 3.6% | 1.0% | 16.6% | 13.1% | 6.0% | 10.0% | 6.7% | · | 4.3% | 4.2% | |
| ROE | 8.9% | 9.1% | 2.3% | 36.3% | 31.3% | 15.2% | 25.7% | 16.6% | · | 11.6% | 10.2% |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.2 | 1.2 | 0.9 | 1.2 | 1.4 | 1.4 | 0.9 | 1.6 | · | 1.3 | 1.5 | |
| Quick Ratio | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 0.8 | · | 0.8 | 1.1 | |
| Debt / Equity | 0.7 | 0.7 | 0.8 | 0.4 | 0.5 | 0.6 | 0.8 | 0.6 | · | 0.6 | 0.5 | |
| LT Debt / Equity | 0.7 | 0.7 | 0.7 | 0.3 | 0.5 | 0.6 | 0.6 | 0.5 | · | 0.5 | 0.4 |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | 0.3 | 0.5 | 0.5 | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | |
| Inventory Turnover | 1.5 | 1.7 | 2.6 | 3.8 | 3.6 | 1.2 | 1.3 | 1.5 | · | 1.7 | 1.5 | |
| Receivables Turnover | 5.4 | 5.5 | 5.3 | 8.9 | 8.4 | 5.7 | 6.2 | 6.6 | · | 6.4 | 5.9 |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $10.95 | $11.16 | $10.25 | $17.50 | $14.24 | $7.44 | $9.12 | $8.98 | · | $8.58 | $7.81 | |
| Cash Flow / Share | $2.05 | $2.24 | $1.52 | $5.11 | $5.71 | $2.56 | $2.22 | $2.65 | · | $2.58 | $2.32 | |
| Dividend / Share | $1.72 | $1.69 | $1.65 | $1.61 | $1.57 | $1.53 | $1.46 | $1.38 | · | $1.22 | · | |
| Dividend Paid / Share | · | · | · | · | · | · | · | · | · | $1.20 | $1.12 | |
| EPS (TTM) | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 | $1.63 | $2.82 | $1.87 | · | $1.17 | $1.11 |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -1.7% | 6.8% | -41.1% | 24.5% | 95.2% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -14.8% | -7.8% | 12.7% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.5% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -3.5% | 281.1% | -93.2% | 42.1% | 136.2% | · | · | · | · | · | · | |
| EPS CAGR 3Y | -37.1% | -28.4% | -39.0% | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.6% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -3.2% | 279.0% | -93.2% | 42.7% | 140.0% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -37.2% | -28.5% | -38.6% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -3.2% | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $62.58B | $63.63B | $59.55B | $101.17B | $81.29B | $41.65B | $40.91B | $40.83B | · | $52.82B | $48.85B | |
| Net Income TTM | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.16B | $16.03B | $11.15B | · | $7.21B | $6.96B | |
| P/E | 18.3 | 18.8 | 77.8 | 9.4 | 15.3 | 22.6 | 13.2 | 22.1 | · | 26.3 | 27.6 | |
| Earnings Yield | 5.5% | 5.3% | 1.3% | 10.7% | 6.5% | 4.4% | 7.6% | 4.5% | · | 3.8% | 3.6% |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.03B | $14.45B | $17.56B | $16.65B | $14.65B | $13.71B | $17.76B | $17.70B | $13.28B | $14.88B | $14.57B | $13.01B | $18.49B | $25.14B | |
| Cost of Revenue | $4.09B | $3.55B | $5.27B | $4.17B | $3.78B | $2.85B | $5.91B | $5.26B | $3.30B | $3.38B | $7.56B | $3.24B | $4.89B | $9.65B | |
| SG&A Expense | $3.41B | $2.96B | $4.16B | $3.19B | $3.42B | $3.03B | $4.27B | $3.24B | $3.72B | $3.50B | $4.58B | $3.50B | $3.42B | $4.64B | |
| Interest Expense | $667M | $668M | $711M | $652M | $654M | $654M | $740M | $783M | $778M | $790M | $688M | $508M | $318M | $313M | |
| Interest Income | $113M | $115M | $166M | $138M | $156M | $143M | $170M | $116M | $130M | $129M | $609M | $316M | $177M | $137M | |
| Other Non-op | $-3.72B | $-861M | $-4.51B | $-517M | $-739M | $-953M | $-2.36B | $-243M | $-1.11B | $-680M | $159M | $75M | $-275M | $1M | |
| Pretax Income | $-653M | $3.17B | $-1.64B | $3.33B | $3.04B | $2.79B | $-10M | $4.71B | $-103M | $3.42B | $-4.13B | $2.27B | $6.27B | $5.23B | |
| Income Tax | $-407M | $461M | $-2M | $-216M | $141M | $-189M | $-421M | $234M | $-134M | $293M | $-795M | $-71M | $715M | $230M | |
| Net Income | $-248M | $2.69B | $-1.65B | $3.54B | $2.91B | $2.97B | $410M | $4.46B | $41M | $3.12B | $-3.37B | $2.33B | $5.54B | $4.99B | |
| EPS (Basic) | $-0.04 | $0.47 | $-0.28 | $0.62 | $0.51 | $0.52 | $0.07 | $0.79 | $0.01 | $0.55 | $-0.59 | $0.41 | $0.98 | $0.88 | |
| EPS (Diluted) | $-0.04 | $0.47 | $-0.29 | $0.62 | $0.51 | $0.52 | $0.07 | $0.78 | $0.01 | $0.55 | $-0.59 | $0.41 | $0.97 | $0.87 | |
| Shares (Basic) | 5,699,000,000 | 5,691,000,000 | · | 5,685,000,000 | 5,685,000,000 | 5,675,000,000 | · | 5,667,000,000 | 5,666,000,000 | 5,657,000,000 | · | 5,646,000,000 | 5,634,000,000 | · | |
| Shares (Diluted) | 5,699,000,000 | 5,731,000,000 | · | 5,714,000,000 | 5,706,000,000 | 5,710,000,000 | · | 5,705,000,000 | 5,696,000,000 | 5,697,000,000 | · | 5,713,000,000 | 5,727,000,000 | · | |
| EBITDA | $1.62B | $1.61B | · | $1.66B | $1.62B | $1.62B | · | · | · | $1.74B | · | · | · | · |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $976M | $1.70B | $1.14B | $1.34B | $1.64B | $1.43B | $1.04B | $1.09B | $1.05B | $719M | · | $2.63B | $2.17B | · | |
| Receivables | $12.49B | $12.59B | $11.87B | $14.26B | $12.08B | $11.85B | $11.46B | $14.45B | $11.39B | $10.99B | · | $10.23B | $12.30B | · | |
| Inventory | $9.95B | $10.67B | $10.65B | $11.47B | $11.67B | $10.85B | $10.85B | $11.72B | $11.45B | $10.89B | · | $10.31B | $9.54B | · | |
| Other Current Assets | $3.52B | $2.91B | $2.81B | $2.36B | $2.69B | $2.95B | $4.25B | $3.85B | $4.19B | $4.37B | · | $4.83B | $5.12B | · | |
| Current Assets | $41.36B | $42.82B | $42.90B | $46.92B | $43.70B | $45.86B | $50.36B | $43.22B | $37.83B | $42.41B | · | $73.35B | $50.08B | · | |
| PP&E (Net) | $19.03B | $19.40B | $19.32B | $18.88B | $18.78B | $18.35B | $18.39B | $18.54B | $18.96B | $18.80B | · | $17.49B | $17.05B | · | |
| PP&E (Gross) | · | · | $36.70B | · | · | · | $34.88B | · | · | · | · | · | · | · | |
| Accum. Depreciation | $18.10B | $17.80B | $17.39B | $17.50B | $17.27B | $16.84B | $16.48B | $16.68B | $16.57B | $16.36B | · | $15.55B | $15.51B | · | |
| Goodwill | $71.42B | $71.41B | $71.26B | $69.10B | $69.00B | $68.44B | $68.53B | $68.57B | $68.44B | $69.30B | $67.78B | $51.57B | $51.48B | $51.38B | |
| Intangibles | $47.05B | $52.56B | $53.73B | $51.32B | $52.70B | $53.98B | $55.41B | $59.99B | $61.24B | $62.83B | · | $41.41B | $42.00B | · | |
| Other Non-current Assets | $9.94B | $9.83B | $9.63B | $9.32B | $9.46B | $9.85B | $9.82B | $10.49B | $10.71B | $11.20B | · | $13.03B | $12.96B | · | |
| Total Assets | $201.13B | $207.62B | $208.16B | $208.73B | $206.09B | $208.03B | $213.40B | $219.48B | $216.19B | $221.09B | · | $220.17B | $195.62B | · | |
| Accounts Payable | $4.58B | $4.51B | $5.24B | $5.02B | $5.17B | $5.24B | $5.63B | $5.31B | $5.11B | $5.59B | · | $6.08B | $6.12B | · | |
| Short-term Debt | · | · | $0 | $0 | $0 | $155M | $2.45B | $5.84B | $7.96B | $6.93B | · | · | · | · | |
| Current Liabilities | $32.65B | $34.35B | $36.98B | $36.60B | $37.73B | $36.45B | $42.99B | $43.21B | $43.82B | $40.50B | · | $34.65B | $36.56B | · | |
| Capital Leases | · | · | $2.29B | · | · | · | $2.29B | · | · | · | · | · | · | · | |
| Deferred Tax | $1.96B | $2.41B | $2.40B | $2.47B | $2.48B | $2.26B | $2.12B | $2.16B | $2.23B | $931M | · | $1.23B | $1.07B | · | |
| Other Non-current Liabilities | $14.78B | $14.20B | $14.72B | $13.61B | $13.93B | $13.30B | $14.15B | $15.57B | $16.09B | $15.12B | · | $13.40B | $13.01B | · | |
| Total Liabilities | $115.64B | $117.21B | $121.39B | $115.64B | $117.08B | $117.39B | $124.90B | $126.92B | $128.22B | $128.54B | · | $120.88B | $94.38B | · | |
| Long-term Debt | $63.10B | $64.43B | $64.64B | $61.66B | $61.75B | $61.39B | $61.15B | $61.75B | $61.25B | $62.31B | · | $64.92B | $35.27B | · | |
| Total Debt | $63.10B | $64.43B | · | $61.66B | $61.75B | $61.54B | · | $67.59B | $69.22B | $69.24B | · | · | · | · | |
| Common Stock | $482M | $482M | $481M | $481M | $481M | $481M | $480M | $480M | $480M | $480M | · | $478M | $478M | · | |
| Paid-in Capital | $95.03B | $94.77B | $94.47B | $94.25B | $94.05B | $93.86B | $93.60B | $93.48B | $93.20B | $93.00B | · | $92.33B | $92.15B | · | |
| Retained Earnings | $112.09B | $117.24B | $114.61B | $121.15B | $117.61B | $119.59B | $116.72B | $121.06B | $116.60B | $121.32B | · | $128.80B | $131.10B | · | |
| Treasury Stock | $115.19B | $115.19B | $115.02B | $115.01B | $115.01B | $115.01B | $114.76B | $114.76B | $114.76B | $114.75B | · | $114.48B | $114.47B | · | |
| AOCI | $-7.22B | $-7.20B | $-8.07B | $-8.07B | $-8.44B | $-8.58B | $-7.84B | $-7.97B | $-7.82B | $-7.76B | · | $-8.10B | $-8.29B | · | |
| Stockholders' Equity | $85.19B | $90.10B | $86.48B | $92.80B | $88.69B | $90.34B | $88.20B | $92.29B | $87.70B | $92.28B | · | $99.02B | $100.97B | · | |
| Liabilities + Equity | $201.13B | $207.62B | $208.16B | $208.73B | $206.09B | $208.03B | $213.40B | $219.48B | $216.19B | $221.09B | · | $220.17B | $195.62B | · |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1.62B | $1.61B | $1.69B | $1.66B | $1.62B | $1.62B | $1.79B | $1.75B | $1.73B | $1.74B | $1.67B | · | $1.49B | $1.52B | |
| Stock-based Comp | $249M | $272M | $225M | $201M | $203M | $170M | $177M | $274M | $206M | $220M | $121M | · | $105M | $364M | |
| Deferred Tax | $-1.32B | $-12M | $-433M | $-765M | $-272M | $-663M | $-396M | $-482M | $-783M | $-441M | $-1.86B | · | $-598M | $-365M | |
| Amort. of Intangibles | · | · | · | $1.20B | $1.20B | $1.20B | · | $1.30B | $1.30B | $1.30B | · | · | · | · | |
| Restructuring | $419M | $49M | $308M | $237M | $-74M | $621M | $656M | $217M | $1.10B | $10M | $1.80B | $138M | $-44M | $514M | |
| Other Non-cash | · | $-3.68B | · | · | · | $-3.68B | · | · | · | $-6.88B | · | · | · | · | |
| Operating Cash Flow | $835M | $2.62B | $5.35B | $4.60B | $-582M | $2.33B | $6.72B | $6.71B | $-1.78B | $1.09B | $5.24B | · | $1.21B | $8.58B | |
| CapEx | $533M | $436M | $845M | $602M | $618M | $564M | $917M | $651M | $637M | $704M | $1.04B | · | $1.14B | $1.00B | |
| Investing Cash Flow | $2.11B | $785M | $-6.15B | $-2.43B | $3.95B | $3.27B | $-1.62B | $-2.06B | $4.60B | $1.73B | $-11.00B | · | $3.31B | $-4.41B | |
| Debt Issued | · | · | $5.99B | $0 | · | · | $0 | $0 | · | · | $0 | · | · | $0 | |
| Net Debt Issued | · | · | · | · | · | $0 | · | · | · | $-1.25B | · | · | $-269M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Financing Cash Flow | $-3.66B | $-2.86B | $596M | $-2.48B | $-3.20B | $-5.23B | $-5.11B | $-4.64B | $-2.46B | $-4.93B | $5.44B | · | $-2.77B | $-5.01B | |
| Net Change in Cash | $-727M | $563M | $-196M | $-301M | $213M | $375M | $-45M | $29M | $343M | $-2.14B | $-316M | · | $1.75B | $-869M | |
| Taxes Paid | $3.47B | $72M | $1.02B | $178M | $3.34B | $152M | $433M | $486M | $2.50B | $184M | $240M | · | $329M | $2.95B | |
| Free Cash Flow | · | $2.18B | · | · | · | $1.77B | · | · | · | $386M | · | · | $73M | · | |
| Levered FCF | · | $1.61B | · | · | · | $1.07B | · | · | · | $-336M | · | · | $-209M | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | -1.7% | 18.6% | · | 21.3% | 19.9% | 21.6% | · | 25.2% | 0.31% | 20.9% | · | 18.3% | 30.3% | · | |
| Pretax Margin | -4.3% | 21.9% | · | 20.0% | 20.8% | 20.3% | · | 26.6% | -0.78% | 23.0% | · | 17.8% | 34.3% | · | |
| EBITDA Margin | 10.8% | 11.2% | · | 10.0% | 11.1% | 11.8% | · | · | · | 11.7% | · | · | · | · | |
| ROA | -0.12% | 1.3% | · | 1.7% | 1.4% | 1.4% | · | 2.1% | 0.02% | 1.5% | · | · | · | · | |
| ROE | -0.29% | 3.0% | · | 3.8% | 3.3% | 3.2% | · | 4.7% | 0.04% | 3.2% | · | · | · | · |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.2 | · | 1.3 | 1.2 | 1.3 | · | 1.0 | 0.9 | 1.0 | · | · | · | · | |
| Quick Ratio | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.3 | 0.3 | · | · | · | · | |
| Debt / Equity | 0.7 | 0.7 | · | 0.7 | 0.7 | 0.7 | · | 0.7 | 0.8 | 0.8 | · | · | · | · | |
| LT Debt / Equity | 0.7 | 0.7 | · | 0.6 | 0.6 | 0.6 | · | 0.6 | 0.7 | 0.7 | · | · | · | · |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | · | · | · | |
| Inventory Turnover | 0.4 | 0.3 | · | 0.4 | 0.3 | 0.3 | · | 0.5 | 0.3 | 0.3 | · | · | · | · | |
| Receivables Turnover | 1.2 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | 1.2 | 1.3 | · | · | · | · |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $2.64 | $2.52 | · | $2.91 | $2.57 | $2.40 | · | $3.10 | $2.33 | $2.61 | · | $2.23 | $3.19 | · | |
| Cash Flow / Share | · | $0.46 | · | · | · | $0.41 | · | · | · | $0.19 | · | · | $0.21 | · | |
| Dividend / Share | $0.86 | $0.00 | $0.86 | $0.00 | $0.86 | $0.00 | $0.85 | $0.00 | $0.84 | $0.00 | $0.83 | $0.82 | $0.00 | $0.41 | |
| EPS (TTM) | $0.76 | $1.31 | · | $1.72 | $1.88 | $1.38 | · | $0.75 | $-0.45 | $-0.05 | · | $3.76 | $5.08 | · |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $63.70B | $63.31B | · | $62.78B | $63.83B | $62.46B | · | $60.43B | $56.22B | $55.95B | · | $79.27B | $94.00B | · | |
| Net Income TTM | $4.33B | $7.49B | · | $9.83B | $10.75B | $7.88B | · | $4.25B | $-2.60B | $-309M | · | $21.47B | $29.05B | · | |
| P/E | 32.0 | 20.6 | · | 13.8 | 12.9 | 18.3 | · | 38.8 | -62.2 | -555.0 | · | 9.8 | 8.0 | · | |
| Earnings Yield | 3.1% | 4.8% | · | 7.2% | 7.8% | 5.5% | · | 2.6% | -1.6% | -0.18% | · | 10.2% | 12.4% | · |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | $62.58B | $63.63B | $59.55B | $101.17B | $81.29B |
| Laba Bersih | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B |
| EPS Dilusian | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Utang / Ekuitas | 0.7 | 0.7 | 0.8 | 0.4 | 0.5 |
| Rasio Lancar | 1.2 | 1.2 | 0.9 | 1.2 | 1.4 |
| Rasio Cepat | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Arus Kas Bebas | $9.07B | $9.84B | $4.79B | $26.03B | $29.87B |
Pemilik institusional (13F) 3.131 pengaju · $107.9B total · Per tanggal 30 Sep. 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 136 (-170 vs Kuartal sebelumnya) | 218 (+51 vs Kuartal sebelumnya) | 1.185 (-142 vs Kuartal sebelumnya) | 1.245 (+127 vs Kuartal sebelumnya) | +44.6M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| VANGUARD GROUP INC | $13.479.519.929 | 541.346.182 | 12,49% | Saham |
| BlackRock, Inc. | $12.754.464.030 | 529.670.433 | 11,82% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.961.368.437 | 372.149.852 | 8,31% | Saham |
| STATE STREET CORP | $7.394.748.800 | 307.090.897 | 6,85% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $3.245.359.604 | 135.275.782 | 3,01% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.871.179.523 | 119.235.030 | 2,66% | Saham |
| Fisher Asset Management, LLC | $2.626.340.379 | 109.067.291 | 2,43% | Saham |
| MORGAN STANLEY | $2.319.998.579 | 96.345.452 | 2,15% | Saham |
| NORGES BANK | $1.481.054.511 | 61.505.586 | 1,37% | Saham |
| NORTHERN TRUST CORP | $1.422.756.518 | 59.084.573 | 1,32% | Saham |
| Bank of New York Mellon Corp | $1.393.739.465 | 57.879.546 | 1,29% | Saham |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $1.381.020.334 | 56.551.011 | 1,28% | Saham |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $1.312.566.125 | 54.508.560 | 1,22% | Saham |
| GOLDMAN SACHS GROUP INC | $1.276.043.730 | 52.991.850 | 1,18% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.265.361.447 | 52.548.228 | 1,17% | Saham |
| BANK OF AMERICA CORP /DE/ | $1.049.601.671 | 43.588.109 | 0,97% | Saham |
| Legal & General Group Plc | $1.041.053.583 | 43.233.122 | 0,96% | Saham |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $969.403.932 | 34.522.932 | 0,90% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $916.633.394 | 38.060.345 | 0,85% | Saham |
| Amundi | $807.487.662 | 33.533.616 | 0,75% | Saham |
| ROYAL BANK OF CANADA | $790.167.000 | 32.814.260 | 0,73% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $770.701.325 | 32.005.869 | 0,71% | Saham |
| DEUTSCHE BANK AG\ | $758.327.792 | 31.492.018 | 0,70% | Saham |
| Invesco Ltd. | $705.717.588 | 29.307.209 | 0,65% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $670.051.958 | 27.826.078 | 0,62% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $582.923.824 | 24.207.800 | 0,54% | Opsi beli |
| JPMORGAN CHASE & CO | $560.759.659 | 23.010.244 | 0,52% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $557.517.016 | 23.152.700 | 0,52% | Opsi jual |
| Capital World Investors | $535.014.038 | 22.218.190 | 0,50% | Saham |
| FIRST TRUST ADVISORS LP | $525.396.686 | 21.818.803 | 0,49% | Saham |
| FEDERATED HERMES, INC. | $501.486.337 | 20.825.845 | 0,46% | Saham |
| WELLS FARGO & COMPANY/MN | $486.263.674 | 20.193.675 | 0,45% | Saham |
| PeakShares LLC | $470.788.000 | 19.551 | 0,44% | Saham |
| CITIGROUP INC | $463.013.015 | 19.228.115 | 0,43% | Saham |
| CITADEL ADVISORS LLC | $459.511.416 | 19.082.700 | 0,43% | Opsi jual |
| AQR CAPITAL MANAGEMENT LLC | $445.018.217 | 18.557.891 | 0,41% | Saham |
| UBS Group AG | $437.007.632 | 18.148.158 | 0,41% | Saham |
| FRANKLIN RESOURCES INC | $428.614.224 | 17.799.594 | 0,40% | Saham |
| California Public Employees Retirement System | $415.668.791 | 17.261.993 | 0,39% | Saham |
| BARCLAYS PLC | $403.262.967 | 16.746.801 | 0,37% | Saham |
| HSBC HOLDINGS PLC | $402.358.982 | 16.704.156 | 0,37% | Saham |
| VAN ECK ASSOCIATES CORP | $399.361.911 | 16.584.797 | 0,37% | Saham |
| Swiss National Bank | $386.334.993 | 16.043.812 | 0,36% | Saham |
| FMR LLC | $370.766.866 | 15.397.294 | 0,34% | Saham |
| Unisphere Establishment | $352.772.000 | 14.650.000 | 0,33% | Saham |
| National Pension Service | $349.892.971 | 14.530.439 | 0,32% | Saham |
| Nuveen, LLC | $347.854.529 | 14.445.787 | 0,32% | Saham |
| AMERIPRISE FINANCIAL INC | $345.898.478 | 14.364.565 | 0,32% | Saham |
| Mitsubishi UFJ Asset Management Co., Ltd. | $338.582.667 | 14.060.742 | 0,31% | Saham |
| LPL Financial LLC | $335.189.276 | 13.919.821 | 0,31% | Saham |
Aktivis & pemilik 5%+ 15 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Pfizer Inc. (“Pfizer”) ×9 pengajuan | 5 Agu 2024 | · | Pengajuan awal | · | SEC |
| Pfizer Inc. (“ Pfizer ”) | 6 Nov. 2020 | · | Pengajuan awal | Investasi pasif | SEC |
| Pfizer Inc. IRS Identification Nos. of above persons (entities only), Pfizer Holdings Europe IRS Identification Nos. of above persons (entities only) ×2 pengajuan | 17 Maret 2016 | · | Pengajuan awal | · | SEC |
| IRS Identification Nos. of above persons (entities only) Pfizer Inc., IRS Identification Nos. of above persons (entities only) Pfizer Holdings Europe | 1 Mei 2015 | · | Pengajuan awal | Investasi pasif | SEC |
| Pfizer Inc., Eclipse Acquisition Corp. ×11 pengajuan | 3 Nov. 2011 | · | Pengajuan awal | M&A / penjualan | SEC |
| Orang pelapor yang tidak diungkapkan | 11 April 2008 | · | Pengajuan awal | M&A / penjualan | SEC |
| G. D. Searle LLC, IRS Identification Nos. of above persons (entities only) Pfizer Inc. | 11 Sep. 2007 | · | Pengajuan awal | · | SEC |
| Pfizer Inc.;, Pfizer Holdings Europe (no IRS Identification No.) ×3 pengajuan | 14 Feb. 2006 | · | Pengajuan awal | · | SEC |
| Pfizer Overseas Pharmaceuticals, Pfizer, Inc. ; ×5 pengajuan | 14 Feb. 2006 | · | Pengajuan awal | · | SEC |
| Pfizer Overseas Pharmaceuticals (formerly named Pfizer Ireland Pharmaceuticals), Pfizer, Inc. ; ×2 pengajuan | 14 Feb. 2006 | · | Pengajuan awal | · | SEC |
| G.D. Searle LLC;, Pfizer, Inc. ; | 2 Feb. 2005 | · | Pengajuan awal | · | SEC |
| Pfizer Ireland Pharmaceuticals, Pfizer Inc.; | 13 Feb. 2004 | · | Pengajuan awal | · | SEC |
| Warner-Lambert Company LLC;, Pfizer Inc. | 17 Sep. 2003 | · | Pengajuan awal | · | SEC |
| Pfizer Holdings Europe, Pfizer Inc. | 24 Maret 2003 | · | Pengajuan awal | · | SEC |
| Orang pelapor yang tidak diungkapkan | 16 Maret 2001 | · | Pengajuan awal | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 89 orang dalam · 26 pejabat · 24 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Albert Bourla | Chairman & CEO | 30 Sep. 2026 A | 429.173 | 1 | 0 | $1.000.920 |
| Jeffrey B Kindler | Former Chairman & CEO | 15 Des. 2010 A | 826.631 | 0 | 0 | $0 |
| Geno J Germano | Group President | 26 Feb. 2015 A | 308.254 | 0 | 0 | $0 |
| Olivier Brandicourt | Business Unit President | 31 Okt. 2013 A | 191.076 | 0 | 0 | $0 |
| David S Simmons | Business Unit President | 31 Mei 2012 A | 179.880 | 0 | 0 | $0 |
| Cavan M. Redmond | Group President | 31 Mei 2012 A | 151.138 | 0 | 0 | $0 |
| Anthony J Maddaluna | Executive Vice President | 30 Des. 2016 A | 112.087 | 0 | 0 | $0 |
| Amy Schulman | Former Exec. Vice President | 31 Des. 2013 A | 223.497 | 0 | 0 | $0 |
| Kristin C Peck | Executive Vice President | 31 Okt. 2012 A | 43.400 | 0 | 0 | $0 |
| Natale S Ricciardi | Senior Vice President | 31 Maret 2011 A | 394.778 | 0 | 0 | $0 |
| Mary S Mcleod | Former Sr. Vice President | 15 Des. 2010 A | 120.833 | 0 | 0 | $0 |
| Martin Mackay | Senior Vice President | 14 Mei 2010 A | 375.044 | 0 | 0 | $0 |
| William R Ringo | Senior Vice President | 31 Maret 2010 A | 252.798 | 0 | 0 | $0 |
| Corey S Goodman | Senior Vice President | 30 April 2009 A | 82.232 | 0 | 0 | $0 |
| Joseph M Feczko | Senior Vice President | 13 Maret 2009 A | 428.855 | 0 | 0 | $0 |
| Richard H Bagger | Senior Vice President | 31 Des. 2008 A | 54.877 | 0 | 0 | $0 |
| Allen P Waxman | Senior Vice President | 28 Feb. 2008 F | 62.341 | 0 | 0 | $0 |
| David L Shedlarz | Vice Chairman | 31 Des. 2007 A | 609.310 | 0 | 0 | $0 |
| John L Lamattina | Senior Vice President | 15 Okt. 2007 A | 383.190 | 0 | 0 | $0 |
| Alan G Levin | Senior Vice President | 14 Sep. 2007 A | 340.061 | 0 | 0 | $0 |
| Sylvia M Montero | Senior Vice President | 29 Des. 2006 A | · | 0 | 0 | $0 |
| Karen L Katen | Vice Chairman | 15 Agu 2006 A | 941.284 | 0 | 0 | $0 |
| Peter B Corr | Senior Vice President | 24 Feb. 2005 A | 148.866 | 0 | 0 | $0 |
| Charles L Hardwick | Senior Vice President | 24 Feb. 2005 A | 70.094 | 0 | 0 | $0 |
| Yvonne R Jackson | Senior VP - Human Resources | 24 Feb. 2005 F | 13.507 | 0 | 0 | $0 |
| John W Mitchell | Senior Vice President | 31 Des. 2004 I | 746.148 | 0 | 0 | $0 |
| Mortimer J Buckley | Direktur | 25 Sep. 2026 A | 37.632 | 1 | 0 | $960.369 |
| Joseph Echevarria | Direktur | 25 Sep. 2026 A | · | 0 | 0 | $0 |
| James C Smith | Direktur | 25 Sep. 2026 A | 1.542 | 0 | 0 | $0 |
| James Quincey | Direktur | 25 Sep. 2026 A | · | 0 | 0 | $0 |
| Cyrus Taraporevala | Direktur | 25 Sep. 2026 A | · | 0 | 0 | $0 |
| Shantanu Narayen | Direktur | 25 Sep. 2026 A | · | 0 | 0 | $0 |
| Marc Tessier-Lavigne | Direktur | 23 April 2015 A | · | 0 | 0 | $0 |
| George A Lorch | Direktur | 24 April 2014 A | 24.126 | 0 | 0 | $0 |
| Constance J Horner | Direktur | 24 April 2014 A | · | 0 | 0 | $0 |
| Anthony M Burns | Direktur | 25 April 2013 A | 23.989 | 0 | 0 | $0 |
| Iii William H Gray | Direktur | 25 April 2013 A | 26 | 0 | 0 | $0 |
| John P Mascotte | Direktur | 26 April 2012 A | 3.940 | 0 | 0 | $0 |
| Michael S Brown | Direktur | 28 April 2011 A | · | 0 | 0 | $0 |
| William C Steere JR | Direktur | 1 April 2011 A | 1.265.131 | 0 | 0 | $0 |
| BURT ROBERT N | Direktur | 22 April 2010 A | 12.200 | 0 | 0 | $0 |
| Dana G Mead | Direktur | 1 April 2010 A | 9.350 | 0 | 0 | $0 |
| William R Howell | Direktur | 24 April 2008 A | · | 0 | 0 | $0 |
| Henry A Mckinnell | Direktur | 28 Feb. 2007 A | 2.134.851 | 0 | 0 | $0 |
| Ruth J Simmons | Direktur | 27 April 2006 A | 1.200 | 0 | 0 | $0 |
| Stanley Ikenberry | Direktur | 27 April 2006 A | · | 0 | 0 | $0 |
| Jean Paul Valles | Direktur | 28 April 2005 A | 641.854 | 0 | 0 | $0 |
| Franklin D Raines | Direktur | 1 April 2005 A | · | 0 | 0 | $0 |
| Pfizer Inc. | Pemilik 10% | 17 Des. 2003 J | 3.273.679 | 0 | 0 | $0 |
| Jennifer B. Damico | · | 5 Agu 2026 S | 28.611 | 0 | 2 | $-134.661 |
| Ronald E Blaylock | · | 5 Agu 2026 P | 66.938 | 1 | 0 | $998.821 |
| Dan R. Littman | · | 23 April 2026 A | · | 0 | 0 | $0 |
| Susan Desmond-Hellmann | · | 23 April 2026 A | · | 0 | 0 | $0 |
| Scott Gottlieb | · | 23 April 2026 A | 10.000 | 0 | 0 | $0 |
| Johnson Suzanne M Nora | · | 23 April 2026 A | 10.000 | 0 | 0 | $0 |
| Andrew Baum | · | 3 Maret 2026 A | · | 0 | 0 | $0 |
| Alexandre De Germay | · | 3 Maret 2026 A | 74.377 | 0 | 0 | $0 |
| Christoffel Boshoff | · | 3 Maret 2026 A | 161.379 | 0 | 0 | $0 |
| Michael Mcdermott | · | 3 Maret 2026 A | 74.308 | 0 | 0 | $0 |
| Aamir Malik | · | 3 Maret 2026 A | 29.548 | 0 | 0 | $0 |
| Payal Sahni | · | 3 Maret 2026 A | 27.667 | 0 | 0 | $0 |
| Douglas M Lankler | · | 3 Maret 2026 A | 163.177 | 0 | 0 | $0 |
| Lidia Fonseca | · | 3 Maret 2026 A | 46.455 | 0 | 0 | $0 |
| David M Denton | · | 3 Maret 2026 A | 37.919 | 0 | 0 | $0 |
| Susan Hockfield | · | 24 April 2025 A | · | 0 | 0 | $0 |
| Sally Susman | · | 4 Maret 2025 A | 168.909 | 0 | 0 | $0 |
| Rady A Johnson | · | 31 Des. 2024 A | 97.153 | 0 | 0 | $0 |
| Mikael Dolsten | · | 12 Sep. 2024 A | 321.729 | 0 | 0 | $0 |
| Helen Hobbs | · | 25 April 2024 A | · | 0 | 0 | $0 |
| Angela Hwang | · | 10 Mei 2023 I | 29.778 | 0 | 0 | $0 |
| William Pao | · | 31 Maret 2023 F | 97.765 | 0 | 0 | $0 |
| William R Carapezzi JR | · | 12 Mei 2022 S | 38.146 | 0 | 0 | $0 |
| Frank A Damelio | · | 26 Feb. 2022 M | 555.941 | 0 | 0 | $0 |
| John D Young | · | 15 Des. 2021 A | 312.704 | 0 | 0 | $0 |
| Alexander R Mackenzie | · | 2 Des. 2021 S | 87.280 | 0 | 0 | $0 |
| James M Kilts | · | 25 Sep. 2020 A | 0 | 0 | 0 | $0 |
| Dawn Rogers | · | 15 Juni 2020 A | 4.823 | 0 | 0 | $0 |
| Don W Cornwell | · | 23 April 2020 A | 0 | 0 | 0 | $0 |
| Michael Goettler | · | 28 Feb. 2020 M | 36.812 | 0 | 0 | $0 |
| Loretta V Cangialosi | · | 28 Feb. 2020 M | 122.075 | 0 | 0 | $0 |
| Ian C Read | · | 4 Maret 2019 S | 1.109.202 | 0 | 0 | $0 |
| Freda C Lewis-Hall | · | 28 Feb. 2019 A | 375.244 | 0 | 0 | $0 |
| Laurie J Olson | · | 13 Agu 2018 S | 72.672 | 0 | 0 | $0 |
| Kirsten Lund-Jurgensen | · | 1 Agu 2018 S | 4.643 | 0 | 0 | $0 |
| Dennis A Ausiello | · | 26 April 2018 A | 887 | 0 | 0 | $0 |
| Stephen W Sanger | · | 29 Maret 2018 A | 85 | 0 | 0 | $0 |
| Charles H Hill | · | 6 Maret 2018 S | 57.328 | 0 | 0 | $0 |
| Frances D Fergusson | · | 27 April 2017 A | · | 0 | 0 | $0 |
| Robert W Norton | · | 31 Des. 2003 A | 248.900 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 165 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| PJP · Invesco Exchange-Traded Fund Trust | 5,58% | 1.093.025 SH | 5 Okt. 2026 | Harian |
| HDV · iShares Trust | 4,66% | 25.857.763 SH | 11 Sep. 2026 | Harian |
| IHE · iShares Trust | 4,56% | 2.670.093 SH | 11 Sep. 2026 | Harian |
| SPHD · Invesco Exchange-Traded Fund Trust … | 3,71% | 4.212.077 SH | 5 Okt. 2026 | Harian |
| PEY · Invesco Exchange-Traded Fund Trust | 2,82% | 1.089.732 SH | 5 Okt. 2026 | Harian |
| IYH · iShares Trust | 2,54% | 3.333.009 SH | 11 Sep. 2026 | Harian |
| PAYR · Federated Hermes ETF Trust | 2,51% | 57.250 NS | 31 Juli 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 2,35% | 985.502 NS | 31 Juli 2026 | N-PORT |
| DVY · iShares Trust | 2,24% | 19.063.533 SH | 11 Sep. 2026 | Harian |
| FDV · Federated Hermes ETF Trust | 2,24% | 787.273 NS | 31 Juli 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 2,06% | 2.705.939 NS | 31 Juli 2026 | N-PORT |
| BMVP · Invesco Exchange-Traded Fund Trust | 2,05% | 73.565 SH | 5 Okt. 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 2,02% | 17.099.868 SH | 19 Agu 2026 | Harian |
| IXJ · iShares Trust | 2,00% | 2.998.095 SH | 11 Sep. 2026 | Harian |
| LYLD · Cambria ETF Trust | 1,95% | 5.645 NS | 31 Juli 2026 | N-PORT |
| GCOW · Pacer Funds Trust | 1,85% | 2.539.373 NS | 31 Juli 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 1,84% | 13.728.675 NS | 31 Juli 2026 | N-PORT |
| DIV · Global X Funds | 1,80% | 565.544 NS | 31 Juli 2026 | N-PORT |
| SPDV · ETF Series Solutions | 1,73% | 90.905 NS | 31 Juli 2026 | N-PORT |
| VLUE · iShares Trust | 1,70% | 5.895.715 SH | 11 Sep. 2026 | Harian |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,65% | 519.314 SH | 5 Okt. 2026 | Harian |
| LQAI · Exchange Listed Funds Trust | 1,64% | 1.459 NS | 31 Juli 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 1,63% | 112.150 NS | 31 Juli 2026 | N-PORT |
| NULV · Nushares ETF Trust | 1,49% | 1.308.622 NS | 31 Juli 2026 | N-PORT |
| DIVB · iShares Trust | 1,30% | 958.549 SH | 11 Sep. 2026 | Harian |
| GDIV · Harbor ETF Trust | 1,30% | 122.064 NS | 31 Juli 2026 | N-PORT |
| DIVD · EA Series Trust | 1,17% | 10.041 NS | 31 Juli 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,11% | 9.176 NS | 31 Juli 2026 | N-PORT |
| FTLS · First Trust Exchange-Traded Fund III | 1,05% | 1.050.211 NS | 31 Juli 2026 | N-PORT |
| EQWL · Invesco Exchange-Traded Fund Trust | 1,02% | 1.014.799 SH | 5 Okt. 2026 | Harian |
| SYLD · Cambria ETF Trust | 0,96% | 382.605 NS | 31 Juli 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,94% | 242.900 NS | 31 Juli 2026 | N-PORT |
| WLDR · Two Roads Shared Trust | 0,91% | 33.339 NS | 31 Juli 2026 | N-PORT |
| BSCQ · Invesco Exchange-Traded Self-Indexe… | 0,90% | 28.655.000 | 5 Okt. 2026 | Harian |
| XT · iShares Trust | 0,90% | 1.255.272 SH | 11 Sep. 2026 | Harian |
| NUDV · Nushares ETF Trust | 0,89% | 17.826 NS | 31 Juli 2026 | N-PORT |
| FDRR · FIDELITY COVINGTON TRUST | 0,81% | 238.562 NS | 31 Juli 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,80% | 2.848.027 SH | 5 Okt. 2026 | Harian |
| DFLV · Dimensional ETF Trust | 0,76% | 2.051.163 NS | 31 Juli 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0,75% | 4.643.669 NS | 31 Juli 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,71% | 399.397 NS | 31 Juli 2026 | N-PORT |
| CVAR · ETF Opportunities Trust | 0,68% | 11.625 NS | 31 Juli 2026 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,65% | 227.695 SH | 5 Okt. 2026 | Harian |
| NULC · Nushares ETF Trust | 0,65% | 18.363 NS | 31 Juli 2026 | N-PORT |
| MGV · VANGUARD WORLD FUND | 0,65% | 3.582.302 SH | 19 Agu 2026 | Harian |
| FHEQ · Fidelity Greenwood Street Trust | 0,65% | 240.601 NS | 31 Juli 2026 | N-PORT |
| IIGD · Invesco Exchange-Traded Self-Indexe… | 0,64% | 175.000 | 5 Okt. 2026 | Harian |
| VMAX · Lattice Strategies Trust | 0,64% | 12.610 NS | 31 Juli 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,61% | 215.331 SH | 19 Agu 2026 | Harian |
| FVAL · FIDELITY COVINGTON TRUST | 0,61% | 323.509 NS | 31 Juli 2026 | N-PORT |
| FEUS · FlexShares Trust | 0,60% | 26.840 NS | 31 Juli 2026 | N-PORT |
| IWX · iShares Trust | 0,58% | 822.366 SH | 11 Sep. 2026 | Harian |
| PFM · Invesco Exchange-Traded Fund Trust | 0,58% | 162.902 SH | 5 Okt. 2026 | Harian |
| VYM · VANGUARD WHITEHALL FUNDS | 0,57% | 22.722.554 SH | 19 Agu 2026 | Harian |
| BKDV · BNY Mellon ETF Trust II | 0,53% | 390.108 NS | 31 Juli 2026 | N-PORT |
| IVE · iShares Trust | 0,53% | 9.466.799 SH | 11 Sep. 2026 | Harian |
| VTV · VANGUARD INDEX FUNDS | 0,51% | 54.192.320 SH | 19 Agu 2026 | Harian |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,50% | 14.919.000 | 5 Okt. 2026 | Harian |
| IUSV · iShares Trust | 0,50% | 4.987.037 SH | 11 Sep. 2026 | Harian |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,50% | 643.000 | 5 Okt. 2026 | Harian |
| OEI · Listed Funds Trust | 0,48% | 8.950 NS | 31 Juli 2026 | N-PORT |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,47% | 1.312.357 SH | 19 Agu 2026 | Harian |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,47% | 156.260 NS | 31 Juli 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,47% | 292.581 NS | 31 Juli 2026 | N-PORT |
| ILCV · iShares Trust | 0,46% | 220.546 SH | 11 Sep. 2026 | Harian |
| FBUF · Fidelity Greenwood Street Trust | 0,45% | 4.314 NS | 31 Juli 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,44% | 127.850 SH | 19 Agu 2026 | Harian |
| IWD · iShares Trust | 0,42% | 12.653.051 SH | 11 Sep. 2026 | Harian |
| LRGF · iShares Trust | 0,41% | 545.518 SH | 11 Sep. 2026 | Harian |
| RPV · Invesco Exchange-Traded Fund Trust | 0,40% | 240.969 SH | 5 Okt. 2026 | Harian |
| DFVX · Dimensional ETF Trust | 0,39% | 82.954 NS | 31 Juli 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,38% | 11.789.000 | 5 Okt. 2026 | Harian |
| IOO · iShares Trust | 0,38% | 1.247.283 SH | 11 Sep. 2026 | Harian |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,38% | 3.436.316 SH | 19 Agu 2026 | Harian |
| FAB · First Trust Exchange-Traded AlphaDE… | 0,36% | 24.124 NS | 31 Juli 2026 | N-PORT |
| EVUS · iShares Trust | 0,36% | 49.268 SH | 11 Sep. 2026 | Harian |
| HAPI · Harbor ETF Trust | 0,34% | 66.415 NS | 31 Juli 2026 | N-PORT |
| EGLE · Global X Funds | 0,33% | 290 NS | 31 Juli 2026 | N-PORT |
| OEF · iShares Trust | 0,33% | 2.412.320 SH | 11 Sep. 2026 | Harian |
| FYEE · Fidelity Greenwood Street Trust | 0,33% | 28.563 NS | 31 Juli 2026 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0,33% | 9.631 NS | 31 Juli 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,33% | 1.144.235 SH | 5 Okt. 2026 | Harian |
| ROUS · Lattice Strategies Trust | 0,31% | 87.648 NS | 31 Juli 2026 | N-PORT |
| USCL · iShares Trust | 0,30% | 301.659 SH | 10 Sep. 2026 | Harian |
| TOPC · iShares Trust | 0,29% | 3.453 SH | 11 Sep. 2026 | Harian |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,28% | 51.648 NS | 31 Juli 2026 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,28% | 169.789 SH | 5 Okt. 2026 | Harian |
| IWL · iShares Trust | 0,28% | 221.494 SH | 11 Sep. 2026 | Harian |
| XVV · iShares Trust | 0,27% | 65.658 SH | 11 Sep. 2026 | Harian |
| DYNF · BlackRock ETF Trust | 0,27% | 4.037.182 SH | 11 Sep. 2026 | Harian |
| FDVV · FIDELITY COVINGTON TRUST | 0,27% | 1.077.066 NS | 31 Juli 2026 | N-PORT |
| MGC · VANGUARD WORLD FUND | 0,26% | 1.139.734 SH | 19 Agu 2026 | Harian |
| PBP · Invesco Exchange-Traded Fund Trust | 0,24% | 33.905 SH | 5 Okt. 2026 | Harian |
| IVV · iShares Trust | 0,24% | 71.807.189 SH | 11 Sep. 2026 | Harian |
| ESGV · VANGUARD WORLD FUND | 0,24% | 1.287.392 SH | 19 Agu 2026 | Harian |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,24% | 917.698 SH | 5 Okt. 2026 | Harian |
| ILCB · iShares Trust | 0,24% | 110.304 SH | 11 Sep. 2026 | Harian |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,23% | 10.388.000 | 5 Okt. 2026 | Harian |
| ESGU · iShares Trust | 0,23% | 1.466.183 SH | 11 Sep. 2026 | Harian |
| ADME · ETF Series Solutions | 0,23% | 26.445 NS | 31 Juli 2026 | N-PORT |
| IYY · iShares Trust | 0,22% | 244.557 SH | 11 Sep. 2026 | Harian |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,22% | 8.058.441 | 5 Okt. 2026 | Harian |
| CRBN · iShares Trust | 0,22% | 94.860 SH | 11 Sep. 2026 | Harian |
| IWB · iShares Trust | 0,22% | 3.940.324 SH | 11 Sep. 2026 | Harian |
| XYLD · Global X Funds | 0,22% | 289.830 NS | 31 Juli 2026 | N-PORT |
| XRMI · Global X Funds | 0,22% | 4.435 NS | 31 Juli 2026 | N-PORT |
| PTLC · Pacer Funds Trust | 0,22% | 288.629 NS | 31 Juli 2026 | N-PORT |
| ACIO · ETF Series Solutions | 0,22% | 208.133 NS | 31 Juli 2026 | N-PORT |
| VV · VANGUARD INDEX FUNDS | 0,22% | 6.656.238 SH | 19 Agu 2026 | Harian |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,22% | 781.780 NS | 31 Juli 2026 | N-PORT |
| TOV · EA Series Trust | 0,22% | 23.725 NS | 31 Juli 2026 | N-PORT |
| XYLG · Global X Funds | 0,22% | 5.634 NS | 31 Juli 2026 | N-PORT |
| GLOF · iShares Trust | 0,22% | 15.931 SH | 11 Sep. 2026 | Harian |
| XTR · Global X Funds | 0,22% | 421 NS | 31 Juli 2026 | N-PORT |
| XCLR · Global X Funds | 0,22% | 312 NS | 31 Juli 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0,22% | 95.884 NS | 31 Juli 2026 | N-PORT |
| BKLC · BNY Mellon ETF Trust | 0,22% | 476.345 NS | 31 Juli 2026 | N-PORT |
| IWV · iShares Trust | 0,22% | 1.569.616 SH | 11 Sep. 2026 | Harian |
| ITOT · iShares Trust | 0,22% | 7.433.657 SH | 11 Sep. 2026 | Harian |
| VOO · VANGUARD INDEX FUNDS | 0,21% | 148.055.512 SH | 19 Agu 2026 | Harian |
| DFUS · Dimensional ETF Trust | 0,21% | 1.719.178 NS | 31 Juli 2026 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0,20% | 7.007.210 SH | 5 Okt. 2026 | Harian |
| SPUU · Direxion Shares ETF Trust | 0,20% | 21.504 NS | 31 Juli 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0,20% | 137.341 NS | 31 Juli 2026 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0,20% | 4.490 SH | 5 Okt. 2026 | Harian |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,20% | 938.753 SH | 19 Agu 2026 | Harian |
| EUSA · iShares, Inc. | 0,20% | 138.171 SH | 11 Sep. 2026 | Harian |
| DCOR · Dimensional ETF Trust | 0,20% | 265.049 NS | 31 Juli 2026 | N-PORT |
| SIZE · iShares Trust | 0,19% | 29.780 SH | 11 Sep. 2026 | Harian |
| VTI · VANGUARD INDEX FUNDS | 0,19% | 180.976.007 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,19% | 479.516 SH | 19 Agu 2026 | Harian |
| DFAU · Dimensional ETF Trust | 0,19% | 932.512 NS | 31 Juli 2026 | N-PORT |
| TOK · iShares Trust | 0,18% | 15.688 SH | 11 Sep. 2026 | Harian |
| TILT · FlexShares Trust | 0,18% | 154.208 NS | 31 Juli 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0,18% | 39.662 NS | 31 Juli 2026 | N-PORT |
| URTH · iShares, Inc. | 0,17% | 511.839 SH | 11 Sep. 2026 | Harian |
| DFSU · Dimensional ETF Trust | 0,17% | 153.594 NS | 31 Juli 2026 | N-PORT |
| PEVC · Pacer Funds Trust | 0,17% | 161 NS | 31 Juli 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0,17% | 445.582 NS | 31 Juli 2026 | N-PORT |
| HDUS · Lattice Strategies Trust | 0,16% | 12.827 NS | 31 Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,15% | 2.930.879 NS | 31 Juli 2026 | N-PORT |
| ACWI · iShares Trust | 0,15% | 1.803.698 SH | 11 Sep. 2026 | Harian |
| LGDX · Tidal Trust III | 0,15% | 8.315 NS | 31 Juli 2026 | N-PORT |
| VOXP · Advisors Series Trust | 0,13% | 303 NS | 31 Juli 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,12% | 4.732.591 SH | 19 Agu 2026 | Harian |
| GSY · Invesco Actively Managed Exchange-T… | 0,11% | 4.039.000 | 5 Okt. 2026 | Harian |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,10% | 177.698 SH | 5 Okt. 2026 | Harian |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 27.339 SH | 5 Okt. 2026 | Harian |
| DXUV · Dimensional ETF Trust | 0,09% | 20.575 NS | 31 Juli 2026 | N-PORT |
| JFLI · J.P. Morgan Exchange-Traded Fund Tr… | 0,09% | 1.786 NS | 31 Juli 2026 | N-PORT |
| QLC · FlexShares Trust | 0,08% | 32.704 NS | 31 Juli 2026 | N-PORT |
| GTO · Invesco Actively Managed Exchange-T… | 0,01% | 359.000 | 5 Okt. 2026 | Harian |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 15 Juli 2026 | Harian |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 15 Juli 2026 | Harian |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15 Juli 2026 | Harian |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 Juli 2026 | Harian |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15 Juli 2026 | Harian |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 15 Juli 2026 | Harian |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15 Juli 2026 | Harian |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 Juli 2026 | Harian |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 Juli 2026 | Harian |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 Juli 2026 | Harian |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 Juli 2026 | Harian |
| BNDX · VANGUARD CHARLOTTE FUNDS | · | · | 15 Juli 2026 | Harian |
| VCEB · VANGUARD WORLD FUND | · | · | 30 Juli 2026 | Harian |
PFE Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
Target Harga 12 Bulan
26 analis · 2026-10-05Target rata-rata $28.91 +5,1%
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| PFE | · | 18.3 | -1.7% | 12.4% | 8.9% | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
| JNJ | · | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| MRK | · | 14.5 | 1.3% | 28.1% | 36.9% | · |
| BMY | · | 15.6 | -0.22% | 14.6% | 40.5% | · |
| RPRX | · | 21.7 | 5.1% | 32.4% | 8.0% | · |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | · |
| VTRS | · | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | · |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.